GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Z

Zai Lab 9688.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

20.96

+14.16%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$460.8m

FY2016FY2025

Net income

−$175.8m

FY2016FY2025

Free cash flow

−$159.1m

FY2016FY2025

Shareholders' equity

$715.4m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$460.8m$50.9m$34.0m$215.0m$144.3m$49.0m$13.0m$129,452——
Gross profit$269.5m$32.0m$21.8m$141.0m$92.1m$32.2m$9.2m$85,862——
Research and development$221.2m$29.9m$33.9m$286.4m$573.3m$222.7m$142.2m$120.3m$39.3m$4.1m
Operating income−$229.8m−$36.0m−$46.7m−$404.4m−$700.1m−$301.8m−$203.2m−$141.8m−$51.4m−$4.9m
Net income−$175.8m−$32.8m−$42.7m−$482.0m−$692.4m−$298.2m−$183.4m−$139.1m−$50.4m−$4.8m
Diluted earnings per share-0.16-0.03-0.44-5.02-7.25-3.41-2.70-2.40-1.53-0.50

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$1.17bn$1.19bn$1.04bn$1.22bn$1.61bn$1.30bn$355.2m$302.0m$249.6m$88.9m
Cash and short-term investments$789.5m$779.7m$806.5m$1.01bn$1.41bn$1.19bn$275.9m$263.3m$229.7m$83.9m
Total liabilities$456.8m$344.9m$240.2m$174.5m$230.0m$128.3m$60.5m$50.9m$14.5m$140.5m
Debt$224.3m$153.5m$15.2m$20.4m$15.5m$18.6m$21.8m$3.6m——
Shareholders' equity$715.4m$840.9m$796.1m$1.05bn$1.38bn$1.17bn$294.7m$251.1m$235.2m−$51.6m
Shares outstanding1,106m1,027m97m96m95m88m68m58m33m10m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$151.0m−$27.4m−$198.2m−$367.6m−$549.2m−$216.1m−$191.0m−$97.5m−$32.4m−$4.1m
Capital spending−$8.1m−$7.8m−$8.5m−$25.0m−$18.9m−$10.7m−$15.2m−$10.1m−$9.1m−$284,253
Free cash flow−$159.1m−$35.2m−$206.7m−$392.6m−$568.2m−$226.7m−$206.3m−$107.7m−$41.5m−$4.4m

Financial ratios

Data as of 29 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Gross margin58.5%62.9%64.1%65.6%63.8%65.8%——
Operating margin-49.9%-63.9%-140.3%-182.7%-482.3%-546.6%——
Net margin-38.1%-64.4%-125.5%-224.1%-479.8%-609.0%——
Return on equity-24.6%-30.6%-42.0%-46.1%-50.2%-25.5%——
Return on assets-15.0%-21.7%-32.3%-39.5%-43.0%-23.0%——
Free cash flow yield-0.7%-0.8%-11.1%-20.2%-31.4%-13.3%——
Revenue growth15.5%49.6%24.0%49.0%194.8%277.0%——
Earnings growth-31.6%-23.2%-30.6%-30.4%132.2%62.6%——
Current ratio2.45x3.51x4.63x8.04x7.78x12.40x——
Debt to equity0.29x0.17x0.01x0.01x0.00x0.00x——
Equity ratio61.0%70.9%76.8%85.7%85.7%90.1%——
Interest coverage-44.05x-113.07x———-1478.48x-662.20x-3531.42x
R&D as a share of sales48.0%58.8%99.7%133.2%397.3%454.9%——
Buybacks as a share of market value-7.7%-958.1%-1.1%-0.6%-9.0%-28.9%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue28.9%56.6%—
Operating income-17.2%-5.3%30.3%
Net income-28.6%-10.0%25.6%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin58.9%61.0%61.7%—
Operating margin-51.9%-94.2%-180.2%—
Net margin-40.8%-96.4%-180.7%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings-10.9-83.9-6.2-0.6-0.9-3.9
Price to sales4.254.17.81.44.323.6

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10-for-1 split · 30 Mar 2022

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.